Behind the revenue headline, the Vertex Q3 2026 results contain a clinical story: a regulatory decision on a kidney drug, a gene-edited therapy for sickle cell disease and beta thalassemia that is growing from a small base, and a set of late-stage studies that will report over the next 18 months. Vertex Pharmaceuticals reported quarterly revenue of $3.44 billion, up 12%, on 2 November 2026 and raised its full-year guidance. This article reads the update through the evidence: what the povetacicept filing rests on, what accelerated approval means, and which readouts matter. It is news reporting and not medical or investment advice.
Vertex Q3 2026 results: the clinical points that matter
- Povetacicept, for IgA nephropathy, is under FDA priority review for accelerated approval, with an action date of 30 November 2026.
- The filing is based on a pre-specified interim analysis at Week 36 of the Phase 3 RAINIER trial.
- CASGEVY generated $99.2 million, up from $16.9 million, and the FDA approved it for children aged 2 and older in July 2026, per the company.
- JOURNAVX, a non-opioid pain medicine, brought in $58.3 million and, per the company, was the most prescribed branded oral pain medicine in the US as of August 2026.
- Inaxaplin, atumelnant, suzetrigine in nerve pain and VX-670 all have data or enrolment milestones within about 18 months.
What the povetacicept filing rests on in the Vertex Q3 2026 results
IgA nephropathy is a chronic kidney disease in which immune deposits build up in the kidney’s filters and can lead to loss of kidney function over time; the National Institute of Diabetes and Digestive and Kidney Diseases explains the condition. In trials, a common early marker is the urine protein-to-creatinine ratio, because protein loss tracks disease activity. A summary of Vertex’s slides reports that at Week 36 patients on povetacicept had a 52.0% reduction in that ratio against 4.3% on placebo, and that 42.2% reached a ratio below 0.5 g/g against 6.2%. We could not find those figures in the company’s release, so treat them as reported and unverified. The release itself confirms the interim design and the priority review but gives no efficacy numbers.
Accelerated approval and the Vertex Q3 2026 results
Accelerated approval lets the FDA approve a drug for a serious condition on a surrogate marker that is reasonably likely to predict clinical benefit, with confirmatory evidence required afterwards, as the FDA describes. In IgA nephropathy, proteinuria has served that role, while longer-term outcomes depend on kidney function over years. The practical consequence for readers is that an approval on 30 November would rest on a short-term marker, and the longer RAINIER follow-up would have to confirm it. An action date is also not an approval: the agency can approve, request more information or issue a complete response. The company states that it is prepared for a launch and that a nephrology field team has been in contact with providers since early 2026, according to the call summary.
Gene editing in the Vertex Q3 2026 results
CASGEVY is a CRISPR-based therapy. It is administered after a patient’s own cells are collected, edited and returned, a process that takes specialised treatment centres, which is why uptake builds slowly. Revenue of $99.2 million in the quarter is up 30% on the previous quarter, and the FDA’s July 2026 approval for ages 2 and above widens the eligible group. The release gives no data on patient numbers or treatment-centre counts, so we cannot translate revenue into patients.
Pain, kidney and endocrine readouts after the Vertex Q3 2026 results
- Suzetrigine in painful diabetic peripheral neuropathy: Phase 3 enrolment is expected to finish by the end of 2026 with results in mid-2027.
- Inaxaplin in kidney disease linked to the APOL1 gene: the AMPLITUDE study is fully enrolled, with an interim analysis planned once the interim cohort reaches 48 weeks and data in early 2027; the FDA granted Breakthrough Therapy designation.
- Atumelnant in congenital adrenal hyperplasia: Phase 3 enrolment of about 150 patients should complete in the first quarter of 2027; a Phase 2/3 study in ACTH-dependent Cushing’s syndrome has begun.
- VX-670 in myotonic dystrophy type 1: interim results from the GALILEO study are expected in the second half of 2026.
- Type 1 diabetes: Vertex is prioritising VX-017, a stem cell-derived islet therapy intended to work regardless of blood type, over zimislecel, which is limited to certain blood types, with pivotal development expected in 2027.
Each of these is a plan, and trials can fail. For a comparison of how another company’s early rare-disease data should be read, see our evidence review of Recursion’s REC-4881 study and our report on Cardurion’s Phase 2 results.
PALSONIFY and rare endocrine disease in the Vertex Q3 2026 results
PALSONIFY (paltusotine) came with the Crinetics acquisition and treats acromegaly, a condition caused by too much growth hormone. It is approved in the US and the EU (April 2026), Japan has accepted a submission and granted orphan drug designation, and Vertex expects European launches in the second half of 2027. September revenue was $10.1 million. The company guides to $40 million to $50 million for 2026.
Cystic fibrosis in the Vertex Q3 2026 results
Cystic fibrosis revenue was $3.27 billion. TRIKAFTA/KAFTRIO fell to $2.44 billion from $2.65 billion, while ALYFTREK rose to $706 million from $247 million; by our own calculation, TRIKAFTA revenue fell about 8%. ALYFTREK is reimbursed in 32 countries, and submissions for children aged 2 to 5 have started. The Cystic Fibrosis Foundation provides patient information on the disease and treatments. Next-generation correctors are in development, which the company labels 3.0 and 4.0 programmes.
Market context from Acumen Research and Consulting
We did not find an Acumen report on cystic fibrosis or IgA nephropathy. For gene-edited therapies such as CASGEVY, Acumen Research and Consulting’s Gene Editing Market report values the global market at USD 18.3 billion in 2024 and projects USD 73.7 billion by 2033, a CAGR of 16.9% for 2025 to 2033, with CRISPR at 42% of 2024 revenue and pharmaceutical and biotechnology companies at 52% of end users. By our own calculation, the endpoints imply about 16.7% a year. The report is a general gene-editing study published in March 2025, so use it as indicative context only.
Questions clinicians and researchers may ask after the Vertex Q3 2026 results
How durable is the proteinuria effect of povetacicept? What safety signals emerged in RAINIER? How many patients have been treated with CASGEVY? Will suzetrigine show benefit in nerve pain? None of these is answered in the release. See more in our pharmaceutical section.
Timeline of the Vertex Q3 2026 results
- April 2026: PALSONIFY approved in the EU.
- July 2026: CASGEVY approved for children aged 2 and older.
- 1 September 2026: Crinetics acquisition closes.
- 2 November 2026: Q3 results.
- 30 November 2026: FDA action date for povetacicept.
General background: surrogate endpoints
A surrogate endpoint is a measurement, such as protein in the urine, used as a stand-in for how a patient feels or functions. They can speed access to medicines, but they sometimes fail to predict outcomes, which is why confirmation is required.
Our analysis of the Vertex Q3 2026 results
In our assessment, the clinical heart of the Vertex Q3 2026 results is the 30 November decision. An approval would be a major step into nephrology, but it would rest on an interim surrogate result that longer follow-up must support.
What is not disclosed in the Vertex Q3 2026 results coverage
- Efficacy and safety figures for povetacicept in the company’s release.
- Patient numbers treated with CASGEVY.
- Outcome of the FDA review.
Risks and caveats
This article uses the company’s release and secondary summaries of its slides, which may contain errors. Forward-looking statements may not come true. This is not medical or investment advice.
What to watch next
- The FDA decision on povetacicept.
- VX-670 interim data in the second half of 2026.
- AMPLITUDE interim data in early 2027.
FAQ
What is povetacicept being reviewed for?
Accelerated approval in IgA nephropathy, with an FDA action date of 30 November 2026.
Is povetacicept approved?
Not as of this report; the FDA has not yet decided.
What is CASGEVY?
A gene-edited therapy for sickle cell disease and beta thalassemia, now approved by the FDA for ages 2 and older, per the company.
How we reported this: we relied on the company’s results release of 2 November 2026, secondary summaries of its slides, public health and regulator pages and the Acumen Research and Consulting report cited above. Our calculations are labelled. Last updated 3 November 2026. This is news reporting and not advice.
